Abstract

Aim

This study aimed to utilise the proficient function of diacerein (DCR) and anti-inflammatory polymers to develop sustained release nanoencapsulated emulgel for potential use in osteoarthritis (OA).

Methods

Chitosan (CHS) and chondroitin sulphate (CS) were employed as natural anti-inflammatory polymers to encapsulate nanoformulation of DCR. Optimised nanoformulation was prepared and characterised by investigating impact of polymers and surfactant on particle size, PDI, and encapsulation efficiency (EE). Afterwards, nanoemulgel of optimised DCR-NPs was formulated and evaluated for transdermal application.

Results

Optimised nanoformulation depicted spherical shape with particle size of 320 nm having PDI and EE of 0.3 ± 0.07 and 82 ± 4% (w/w), respectively. DCR-nanoemulgel depicts sustained action of drug up to 96 h with enhanced permeation activity and non-irritancy index.

Conclusions

The elaborated nanoemulgel sustained release of drug having superior penetration properties with provision of enhanced therapeutic effect owing to the presence of CHS, CS, and Argan oil possessing indelible anti-inflammatory attributes.

中文翻译：

---

纳米胶囊双醋瑞因乳剂在骨关节炎中的潜在用途的开发、优化和评估

摘要

目的

本研究旨在利用双醋瑞因 (DCR) 和抗炎聚合物的丰富功能开发用于骨关节炎 (OA) 潜在用途的缓释纳米胶囊乳剂。

方法

壳聚糖 (CHS) 和硫酸软骨素 (CS) 被用作天然抗炎聚合物来封装 DCR 的纳米制剂。通过研究聚合物和表面活性剂对粒径、PDI 和封装效率 (EE) 的影响，制备并表征了优化的纳米制剂。之后，配制优化的 DCR-NPs 的纳米乳液并对其进行透皮应用评估。

结果

优化的纳米制剂描绘了球形，粒径为 320 nm，PDI 和 EE 分别为 0.3 ± 0.07 和 82 ± 4% (w/w)。DCR-nanoemulgel 描述了药物长达 96 小时的持续作用，具有增强的渗透活性和无刺激性指数。

结论

由于存在具有不可磨灭的抗炎特性的 CHS、CS 和摩洛哥坚果油，精心设计的纳米乳凝胶缓释药物具有卓越的渗透特性，并提供增强的治疗效果。